Status:
UNKNOWN
Long Antagonist Protocol for IVF With Single Luteal Dose of Degarelix
Lead Sponsor:
Assisting Nature
Conditions:
Pregnancy, Ovarian
Eligibility:
FEMALE
18-39 years
Phase:
PHASE3
Brief Summary
A prospective study of three different doses of Degarelix in late luteal phase of women undergoing ovarian stimulation for IVF
Detailed Description
A prospective study of three different doses of Degarelix in late luteal phase of women undergoing ovarian stimulation for IVF:Single dose of Degarelix 24mg, 16mg and 12 mg, on day 24th of previous lu...
Eligibility Criteria
Inclusion
- primary infertility
- age 18-39 years; body mass index (BMI) 18-29kg/m2;
- regular menstrual cycle of 26-35days,
- presumed to be ovulatory;
- early follicular- phase serum concentration of FSH within normal limits (1-12 IU/l).
Exclusion
- women with diabetes and other metabolic disease
- women with heart disease, QT prolongation,heart failure
- elevated liver enzymes, liver failure, hepatitis
- women with inflammatory or autoimmune disease
- abnormal karyotype;
- polycystic ovarian syndrome,
- endometriosis stage III/IV;
- history of being a 'poor responder',
- defined as \>20 days of gonadotrophin in a previous stimulation cycle, or any previous cancellation of a stimulation cycle due to limited follicular response, or development of less than 4 follicles 15 mm in a previous stimulation cycle; history of recurrent miscarriage; severe OHSS in a previous stimula- tion cycle or any contraindication for the use of gonadotrophins.
Key Trial Info
Start Date :
February 15 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2021
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT03240159
Start Date
February 15 2017
End Date
June 30 2021
Last Update
October 8 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assisting Nature
Thessaloniki, Greece, 57001